What is AURA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.68B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for AURA?

P/E (TTM) is n/a and 52-week range is $4.73 to $9.54 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s AURA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for AURA?

The company profile lists net income (TTM) near $-182M, EPS (TTM) near $-1.76 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Aura Biosciences Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Boston, Massachusetts, US, 103.4M shares outstanding, ISIN US05153U1079 when available from company profile and filing metadata.

Aura Biosciences Inc

$AURA

Health Care · Biotechnology

IR Run Scenarios

$6.54

+0.54%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The company is headquartered in Boston, Massachusetts and currently employs 113 full-time employees. The company went IPO on 2021-10-29. The Company’s lead candidate, bel-sar (AU-011), is in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. The company is developing bel-sar as a potential first-line vision-sparing treatment option for early intervention in small choroidal melanoma and/or indeterminate lesions, avoiding the need for radiotherapy and reducing the risk for metastasis for these patients. Bel-sar is a virus-like drug conjugate (VDC) consisting of a human papillomavirus (HPV)-derived virus-like particle (VLP) and a phthalocyanine dye, a light-activated cytotoxic payload. The Company’s platform is designed to enable the targeting of a broad range of solid tumors using VLP, that can be conjugated with drugs or loaded with nucleic acids to create VDCs.

Employees

113

Website

aurabiosciences.com/

IPO

2021-10-29

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)